Standout Papers

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis fact... 2009 2026 2014 2020 418
  1. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial (2009)
    Josef S Smolen, Jonathan Kay et al. The Lancet

Immediate Impact

1 by Nobel laureates 52 from Science/Nature 91 standout
Sub-graph 1 of 18

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Rheumatoid arthritis
2023 Standout
11 intermediate papers

Works of Frederick T. Murphy being referenced

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009 Standout
Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial
2008
and 1 more

Author Peers

Author Last Decade Papers Cites
Frederick T. Murphy 970 429 156 418 30 1.7k
Leo B. A. Van De Putte 1362 368 428 609 34 2.5k
F C Breedveld 1309 383 215 618 74 2.3k
Anthony Sebba 938 441 106 386 35 1.9k
Roland Axmann 1067 297 190 520 24 2.4k
J Rovenský 1348 574 173 522 47 2.2k
Leena Paimela 1497 499 230 271 62 2.5k
P. Emery 1539 339 178 464 35 2.6k
H. M. Markusse 1426 543 186 193 43 2.1k
Graeme J. Carroll 680 183 95 236 65 1.6k
Solveig Wållberg‐Jonsson 1738 315 120 436 50 2.4k

All Works

Loading papers...

Rankless by CCL
2026